دورية أكاديمية
أعرض في EDS

Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.

التفاصيل البيبلوغرافية
العنوان: Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
المؤلفون: Miaskowski C; School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA. chris.miaskowski@ucsf.edu., Mastick J; School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA., Paul SM; School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA., Abrams G; Schools of Medicine, University of California, San Francisco, CA, USA., Cheung S; Schools of Medicine, University of California, San Francisco, CA, USA., Sabes JH; Schools of Medicine, University of California, San Francisco, CA, USA., Kober KM; School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA., Schumacher M; Schools of Medicine, University of California, San Francisco, CA, USA., Conley YP; School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA., Topp K; Schools of Medicine, University of California, San Francisco, CA, USA., Smoot B; Schools of Medicine, University of California, San Francisco, CA, USA., Mausisa G; School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA., Mazor M; School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA., Wallhagen M; School of Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA., Levine JD; Schools of Medicine, University of California, San Francisco, CA, USA.
المصدر: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2018 Apr; Vol. 12 (2), pp. 234-245. Date of Electronic Publication: 2017 Nov 20.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 101307557 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-2267 (Electronic) Linking ISSN: 19322259 NLM ISO Abbreviation: J Cancer Surviv Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, N.Y. : Springer Science + Business Media, c2007-
مواضيع طبية MeSH: Cost of Illness* , Neurotoxicity Syndromes*/complications , Neurotoxicity Syndromes*/epidemiology , Neurotoxicity Syndromes*/psychology , Peripheral Nervous System Diseases*/chemically induced , Peripheral Nervous System Diseases*/complications , Peripheral Nervous System Diseases*/epidemiology , Peripheral Nervous System Diseases*/psychology , Quality of Life*, Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Cancer Survivors/*psychology , Cancer Survivors/*statistics & numerical data, Adult ; Aged ; Comorbidity ; Employment/psychology ; Employment/statistics & numerical data ; Female ; Hearing Loss/chemically induced ; Hearing Loss/epidemiology ; Hearing Loss/psychology ; Humans ; Male ; Middle Aged ; Postural Balance/drug effects ; Sensation Disorders/chemically induced ; Sensation Disorders/epidemiology ; Sensation Disorders/psychology ; Surveys and Questionnaires ; Tinnitus/chemically induced ; Tinnitus/epidemiology ; Tinnitus/psychology
مستخلص: Purpose: Limited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors' symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapy-induced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions.
Methods: Survivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated.
Results: Of the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (all p < .05).
Conclusions: Findings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in survivors who received neurotoxic CTX.
Implications for Cancer Survivors: Survivors need to be evaluated for these neurotoxicities and receive appropriate interventions. Referrals to audiologists and physical therapists are warranted to improve survivors' hearing ability, functional status, and QOL.
References: Support Care Cancer. 2014 Apr;22(4):911-7. (PMID: 24249424)
Arch Phys Med Rehabil. 2006 Nov;87(11):1478-85. (PMID: 17084123)
J Clin Oncol. 2012 Jul 1;30(19):2408-17. (PMID: 22547603)
J Pain. 2015 Feb;16(2):186-96. (PMID: 25433166)
J Clin Oncol. 2009 Jan 10;27(2):317-8; author reply 318-9. (PMID: 19064953)
Lancet Oncol. 2017 Jan;18(1):e11-e18. (PMID: 28049573)
PLoS One. 2013;8(3):e59728. (PMID: 23533644)
J Health Soc Behav. 1983 Dec;24(4):385-96. (PMID: 6668417)
Arch Otolaryngol Head Neck Surg. 1997 Sep;123(9):978-81. (PMID: 9305250)
J Behav Med. 2008 Jun;31(3):179-88. (PMID: 18193350)
Medicine (Baltimore). 2016 Nov;95(44):e5312. (PMID: 27858911)
BMC Med Res Methodol. 2006 Jul 27;6:36. (PMID: 16872536)
Sleep. 1992 Dec;15(6):493-8. (PMID: 1475563)
Arch Phys Med Rehabil. 2008 Dec;89(12):2309-15. (PMID: 18976981)
Psychooncology. 2011 Feb;20(2):194-202. (PMID: 20213858)
Br J Cancer. 1998 Apr;77(8):1355-62. (PMID: 9579846)
Front Psychol. 2015 Feb 24;6:118. (PMID: 25759675)
Gynecol Oncol. 2017 Apr;145(1):148-153. (PMID: 28202195)
BMC Musculoskelet Disord. 2008 Jun 23;9:92. (PMID: 18573212)
Support Care Cancer. 2006 Oct;14(10):988-98. (PMID: 16794811)
Support Care Cancer. 2013 Jul;21(7):2059-66. (PMID: 23446880)
Res Nurs Health. 1983 Sep;6(3):117-26. (PMID: 6556698)
Lancet. 2013 Nov 9;382(9904):1600-7. (PMID: 23827090)
J Natl Cancer Inst. 2014 Mar 12;106(5):null. (PMID: 24623533)
Acta Otorhinolaryngol Ital. 2008 Oct;28(5):239-42. (PMID: 19186452)
Postgrad Med J. 2002 Sep;78(923):541-2. (PMID: 12357015)
J Natl Compr Canc Netw. 2014 Nov;12(11):1526-31. (PMID: 25361799)
J Diabetes Complications. 2011 Jan-Feb;25(1):44-51. (PMID: 19896871)
Psychiatry Res. 1991 Mar;36(3):291-8. (PMID: 2062970)
Psychosom Med. 1979 May;41(3):209-18. (PMID: 472086)
Br J Psychiatry. 2002 Mar;180:205-9. (PMID: 11872511)
Cancer Nurs. 2011 Jul-Aug;34(4):E10-20. (PMID: 21242773)
Qual Life Res. 1995 Dec;4(6):523-31. (PMID: 8556012)
Med Oncol. 2015 Jul;32(7):200. (PMID: 26071124)
Diabetologia. 2007 Nov;50(11):2305-12. (PMID: 17846743)
J Affect Disord. 2016 Jun;197:94-9. (PMID: 26985740)
Int J Gynecol Cancer. 2003 Jul-Aug;13(4):428-34. (PMID: 12911718)
Audiology. 2000 Sep-Oct;39(5):284-91. (PMID: 11093613)
Cancer. 2008 Oct 15;113(8):2205-14. (PMID: 18780322)
Acta Otolaryngol. 2017 Apr;137(4):426-431. (PMID: 28084177)
Clin J Pain. 2008 Jul-Aug;24(6):550-5. (PMID: 18574365)
Psychoneuroendocrinology. 2016 Sep;71:127-35. (PMID: 27262345)
Behav Res Ther. 2003 Dec;41(12):1489-96. (PMID: 14705607)
Med Care. 1996 Mar;34(3):220-33. (PMID: 8628042)
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:394-6. (PMID: 16515631)
J Clin Oncol. 2007 Feb 20;25(6):708-14. (PMID: 17228018)
Psychooncology. 2005 Jan;14(1):70-8. (PMID: 15386786)
Sci Rep. 2017 Jan 30;7:41521. (PMID: 28134346)
J Pain Symptom Manage. 1999 May;17(5):320-32. (PMID: 10355211)
J Clin Psychol Med Settings. 2013 Mar;20(1):25-32. (PMID: 22739661)
J Pain Symptom Manage. 2017 Aug;54(2):204-218.e2. (PMID: 28063866)
J Exp Clin Cancer Res. 2003 Mar;22(1):155-8. (PMID: 12725337)
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93. (PMID: 17362317)
Cancer. 2016 Jun 1;122(11):1647-58. (PMID: 26859792)
Eur J Cancer. 2005 Nov;41(17):2613-9. (PMID: 16226458)
Int J Cancer Suppl. 1999;12:132-7. (PMID: 10679884)
Eur J Cancer. 1996 Jun;32A(7):1185-8. (PMID: 8758251)
Annu Rev Public Health. 2014;35:139-52. (PMID: 24641557)
Cancer Nurs. 1990 Apr;13(2):108-15. (PMID: 2331691)
Lancet Oncol. 2017 Jan;18(1):e19-e29. (PMID: 28049574)
Arch Phys Med Rehabil. 1986 Jun;67(6):387-9. (PMID: 3487300)
Breast. 2009 Oct;18(5):279-83. (PMID: 19683445)
J Clin Oncol. 2008 Feb 1;26(4):599-605. (PMID: 18235118)
J Pharmacol Exp Ther. 2014 Nov;351(2):327-35. (PMID: 25194019)
Hear Res. 2016 Mar;333:255-265. (PMID: 26342399)
Nurs Clin North Am. 1995 Dec;30(4):609-24. (PMID: 7501531)
Oncology. 2006;70(3):177-84. (PMID: 16757924)
J Clin Oncol. 2016 Aug 10;34(23 ):2712-20. (PMID: 27354478)
Clin Epidemiol. 2013 Nov 01;5(Suppl 1):3-29. (PMID: 24227920)
Psychol Med. 2017 Jul;47(10 ):1733-1743. (PMID: 28193310)
معلومات مُعتمدة: K05 CA168960 United States CA NCI NIH HHS; R01 CA151692 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Balance; Chemotherapy; Hearing loss; Peripheral neuropathy; Survivor; Tinnitus
تواريخ الأحداث: Date Created: 20171122 Date Completed: 20190513 Latest Revision: 20240620
رمز التحديث: 20240620
مُعرف محوري في PubMed: PMC5886787
DOI: 10.1007/s11764-017-0662-8
PMID: 29159795
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا